Skip to content
Screener

Harmony Biosciences Holdings, Inc. HRMY Cash & Equivalents

Cash & Equivalents at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$667.5M-64.1%
Alkermes logo
AlkermesALKS
$511.53M-1.9%
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
$305.11M+1.4%
Stoke Therapeutics, Inc. logo
Stoke Therapeutics, Inc.STOK
$155.66M-43.4%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$127.64M+78.4%
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$384.99M+51.8%

Other financials

Income statement

See full
Revenue$215.4M+16.6%
Gross profit$170.9M+11.9%
Operating income$37.3M-33.7%
Net income$32.5M-28.7%
EPS (diluted)$0.55-29.5%

Balance sheet

See full
Total debt$164.6M-7.2%
Total equity$910.3M+26.3%
Total assets$1.3B+20.5%

Cash flow

See full
Operating cash flow$27.8M-18.3%
CapEx$107.0K-79.1%
Free cash flow$126.0M+67.9%

Valuation

See full
Market cap$2.26B+13.1%
Enterprise value$1.83B+12.9%
P/E15.5×+4.5×
P/S2.5×-0.1×

Profitability

See full
Gross margin76.5%-1.8pp
Operating margin21.1%-5.1pp
Net margin16.2%-4.3pp
FCF margin40.1%+9.5pp

Returns & leverage

See full
Return on equity17.9%-6.9pp
Debt / equity0.2×-0.1×
Current ratio3.6×-0.1×

Where this comes from

Reported directly by Harmony Biosciences Holdings, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.

The source filing: Harmony Biosciences Holdings, Inc.’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 8:16 AM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001104659-26-056720
Line itemMarch 31, 2026December 31, 2025
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$589,398$752,502
Investments, short-term51,52022,838
Trade receivables, net108,22296,787
Inventory, net5,2815,357
Prepaid expenses16,80116,014
Other current assets7,59513,516

Item 1. Financial Statements

FAQ

What is Harmony Biosciences Holdings, Inc.'s cash & equivalents?
Harmony Biosciences Holdings, Inc. (HRMY) reported cash & equivalents of $589.4M in Q1 2026.
How has Harmony Biosciences Holdings, Inc.'s cash & equivalents changed year-over-year?
Harmony Biosciences Holdings, Inc.'s cash & equivalents increased by 20.5% year-over-year, from $489M to $589.4M.
What is the long-term trend for Harmony Biosciences Holdings, Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Harmony Biosciences Holdings, Inc.'s cash & equivalents has grown at a 26.9% compound annual growth rate (CAGR), from $228.63M to $752.5M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Harmony Biosciences Holdings, Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude